Please login to the form below

Not currently logged in

FDA approves Daiichi Sankyo's Tribenzor

The US Food and Drug Administration has approved Daiichi Sankyo's Tribenzor – a combination drug for high blood pressure

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo's Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) – a combination drug for high blood pressure.

The drug is not approved for initial use, but can be administered to patients suffering from hypertension whose condition is not controlled by a combination of any two of the specified antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics.

Tribenzor works as a combination of medications to relax blood vessels so blood can flow more freely. Olmesartan medoxomil blocks angiotensin II receptors; amlodipine blocks calcium entering into the blood vessel walls; and hydrochlorothiazide reduces water volume in the blood.

Olmesartan is sold by Daiichi under the brandnames Benicar and Olmetec; amlodipine is sold by Pfizer as Norvasc; and hydrochlorothiazide is available both as a generic and as branded products sold by a range of manufacturers.

Around 56 per cent of patients currently in treatment for the condition do not reach existing recommendations in blood pressure levels, according to Daiichi Sankyo. More than two-thirds of patients with high blood pressure will be prescribed two or more antihypertensive medications to reach these outcomes.

"Generally speaking, it can be a struggle for some patients who need to take multi-pill regimens to take their medications as prescribed," said Dr Joseph L Izzo, chief of medicine, Erie County Medical Center, Buffalo, New York.

"Tribenzor is a three-in-one pill that offers a simple, convenient and consistently effective therapy for patients, and may be just what some patients need to help bring their blood pressure to goal," he continued.

27th July 2010


Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....